The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Reform agenda puts China's economic superagency under scrutiny

Mon, 15th Jul 2013 21:02

By Alexandra Harney

SHANGHAI, July 16 (Reuters) - Behind China's twoinvestigations into irregular pricing of infant formula andpharmaceuticals announced this month is one powerful institutionand its struggle for relevance as Beijing attempts a transitionto a more consumption-led economy.

The investigations have entangled big foreign companiesincluding Danone SA, Nestle SA andGlaxoSmithKline Plc. But some analysts say there may besomething deeper at work - jockeying over the direction ofpolicy in the world's second largest economy in the years ahead.

The National Development and Reform Commission (NDRC),Beijing's economic superagency, sets policy for strategicindustries, approves big investments, mergers and acquisitions,and has the authority to influence prices for everything fromliquor to gasoline.

Its powers are so sweeping that it is often called the"little State Council".

But in recent months, as President Xi Jinping and Premier LiKeqiang have begun an attempt to steer China's economy away fromits reliance on state-led investment towards a moreconsumer-focused model, academics and even senior officials havebegun to publicly cast doubt on the NDRC's role.

While the NDRC has always had a price-setting role, itsdecision to launch high profile predatory pricing probes intoinfant formula and drugs now could be a bid by the commission toprove its usefulness as a regulator.

"On a fundamental level, the NDRC is scrambling to show thatit has something to contribute," says Barry Naughton, professorat the University of California, San Diego, and a specialist inChina's economy.

SHIFTING PRIORITIES

That the main economic policy body in the fastest-growingmajor economy over the past decade might feel the need to shoreup its position says much about the debate raging among Chinesepolicymakers. In key areas, the new leaders are trying to shiftChina's priorities in ways that represent a challenge to theNDRC's traditional dominance.

Evidence that dominance could be under threat includes thefact that Premier Li made the reduction of bureaucraticapprovals - one of the NDRC's main roles - a key plank of hisreform plan announced in March.

In May, Li also rejected a 40 trillion yuan ($6.5 trillion)urbanisation plan that the NDRC had proposed, sources familiarwith the matter told Reuters, although the commission deniesthis.

Xi and Li remain committed to urbanisation, but the push nowis "less about building stuff", says Arthur Kroeber, managingdirector of GaveKal Dragonomics Research, and more about helpingmigrants live "more fully-fledged urban lives".

Reducing bureaucratic red tape - such as the NDRC approvalsprocess - is another way the new administration would like toshrink the role of the state in the economy.

There are also concerns among academics about the NDRC as aninstitution. Founded in 1952 as the State Planning Commission,it is deeply rooted in China's command economy past, even as itcrafts policies for its mostly capitalist present.

Part of the debate is about whether, through its investmentapproval function, the NDRC is allocating resources asefficiently as possible, says Shi Lei, professor of economics atFudan University. Overcapacity plagues many industries in China.

With so much power concentrated in one institution,corruption is another worry - Liu Tienan, former NDRC vicechairman, is under investigation over allegations he took bribesto help a businessman defraud banks.

REGULATORY ROLE

The NDRC is no stranger to controversy. It has facedchallenges to its power before and has found ways to survive andeven increase its influence.

Indeed, this month's drugs and formula investigations couldwell be a sign that the NDRC is adapting to the new mood inBeijing by strengthening its role as a regulator.

Especially since the 2011 introduction of regulationsgoverning its role in implementing the 2008 Anti-Monopoly Law,the NDRC has been stepping up its investigations into pricingpractices.

In March, it imposed a 449 million yuan fine on two domesticliquor firms for setting minimum resale prices and a 10 millionyuan fine on eight real estate companies for misleadingcustomers and violating pricing regulations.

In January, it found six foreign LCD manufacturers guilty ofprice fixing and fined them 353 million yuan.

Few sectors pack the symbolic punch of infant formula, bothfor Chinese consumers and the government. Since 2008, whenmelamine in infant formula killed six babies and sickened300,000 others, the infant formula industry has epitomized thetrade-off between rapid economic growth and health and safety.

Driving down prices also supports Beijing's efforts to shiftthe economy away from a reliance on exports and investmenttoward a greater dependence on consumption. Drugs and infantformula are both commonly perceived as too expensive.

"Every time price reductions are made, it's mainly a publicrelations exercise," said Zhou Zhang, an analyst at ChinaMerchant Securities. "The NDRC trumpets how big reductions willbe, but when it comes down to it, prices only fall a bit. TheNDRC's main consideration is public relations."

The NDRC did not respond to a request for comment. Oneperson with knowledge of the NDRC investigations said that theywere being conducted at an unusually rapid pace.

The infant formula investigation also appears to cover notcollusion among companies, but how the retail prices for theseproducts are set - an issue where China's laws differ from thosein other countries, including the United States.

All of the infant formula companies targeted have reducedprices in China since the NDRC announced its investigation.

That might be good for consumers in the short term, butScott Kennedy, director of the Research Center for ChinesePolitics & Business at Indiana University, questioned the NDRC'scredentials as a consumer watchdog, given its central role inChina's export- and investment-led expansion of the past twodecades.

"This is an economy built by, for and of industry," he said.

More News
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.